Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI

Por Akhenblit, Paul J., Hanke, Neale T., Gill, Alexander, Persky, Daniel O., Howison, Christine M., Pagel, Mark D., Baker, Amanda F.
Publicado no Mol Imaging (2016)

Alisertib (MLN8237) an Investigational Agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines suppo...

Por Qi, Wenqing, Spier, Catherine, Liu, Xiaobing, Agarwal, Amit, Cooke, Laurence S., Persky, Daniel O, Chen, Deyu, Miller, Thomas P., Mahadevan, Daruka
Publicado em 2012

Aurora Inhibitor MLN8237 in Combination with Docetaxel Enhances Apoptosis and Antitumor Activity in Mantle Cell Lymphoma

Por Qi, Wenqing, Cooke, Laurence S., Liu, Xiaobing, Rimsza, Lisa, Roe, Denise J., Manziolli, Ann, Persky, Daniel O., Miller, Thomas P., Mahadevan, Daruka
Publicado em 2011

Aurora A inhibitor (MLN8237) plus Vincristine plus Rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma

Por Mahadevan, Daruka, Stejskal, Amy, Cooke, Laurence S., Manziello, Ann, Morales, Carla, Persky, Daniel O., Fisher, Richard I., Miller, Thomas P., Qi, Wenqing
Publicado no Clin Cancer Res (2012)

Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2

Por Mahadevan, Daruka, Morales, Carla, Cooke, Laurence S., Manziello, Ann, Mount, David W., Persky, Daniel O., Fisher, Richard I., Miller, Thomas P., Qi, Wenqing
Publicado em 2014

A Phase II Trial of Single Agent Bevacizumab in Patients with Relapsed, Aggressive Non-Hodgkin Lymphoma: Southwest Oncology Group Study S0108

Por Stopeck, Alison T., Unger, Joseph, Rimsza, Lisa M., Bellamy, William T., Iannone, Maria, Persky, Daniel O., LeBlanc, Michael, Fisher, Richard I., Miller, Thomas P.
Publicado em 2009

Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

Por Li, Lingxiao, Pongtornpipat, Praechompoo, Tiutan, Timothy, Kendrick, Samantha L., Park, Soyoung, Persky, Daniel O., Rimsza, Lisa M., Puvvada, Soham D., Schatz, Jonathan H.
Publicado no Leukemia (2015)

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemother...

Por Persky, Daniel O., Dornan, David, Goldman, Bryan H., Braziel, Rita M., Fisher, Richard I., LeBlanc, Michael, Maloney, David G., Press, Oliver W., Miller, Thomas P., Rimsza, Lisa M.
Publicado em 2012

Reply to “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Haematologica. 2012;97(11):e45

Por Persky, Daniel O., Dornan, David, Goldman, Bryan H., Braziel, Rita M., Fisher, Richard I., LeBlanc, Michael, Maloney, David G., Press, Oliver W., Miller, Thomas P., Rimsza, Lisa M.
Publicado em 2012

Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma

Por Stasik, Christopher J., Nitta, Hiroaki, Zhang, Wenjun, Mosher, Charles H., Cook, James R., Tubbs, Raymond R., Unger, Joseph M., Brooks, Tracy A., Persky, Daniel O., Wilkinson, Sarah T., Grogan, Thomas M., Rimsza, Lisa M.
Publicado em 2010

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Por Persky, Daniel O., Miller, Thomas P., Unger, Joseph M., Spier, Catherine M., Puvvada, Soham, Stea, B. Dino, Press, Oliver W., Constine, Louis S., Barton, Kevin P., Friedberg, Jonathan W., LeBlanc, Michael, Fisher, Richard I.
Publicado no Blood (2015)

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-Cell lymphomas: SWOG S0520

Por Puvvada, Soham, Li, Hongli, Rimsza, Lisa M., Bernstein, Steven H., Fisher, Richard I., LeBlanc, Michael, Schmelz, Monika, Glinsmann-Gibson, Betty, Miller, Thomas P., Maddox, Anne-Marie, Friedberg, Jonathan W., Smith, Sonali M., Persky, Daniel O.
Publicado no Leuk Lymphoma (2016)

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Por Rimsza, Lisa M., LeBlanc, Michael L., Unger, Joseph M., Miller, Thomas P., Grogan, Thomas M., Persky, Daniel O., Martel, Ralph R., Sabalos, Constantine M., Seligmann, Bruce, Braziel, Rita M., Campo, Elias, Rosenwald, Andreas, Connors, Joseph M., Sehn, Laurie H., Johnson, Nathalie, Gascoyne, Randy D.
Publicado no Blood (2008)

Genetic polymorphisms in oxidative stress related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

Por Gustafson, Heather L., Yao, Song, Goldman, Bryan H., Lee, Kristy, Spier, Catherine M., LeBlanc, Michael L., Rimsza, Lisa M., Cerhan, James R., Habermann, Thomas M., Link, Brian K., Maurer, Matthew J., Slager, Susan L., Persky, Daniel O., Miller, Thomas P., Fisher, Richard I., Ambrosone, Christine B., Briehl, Margaret M.
Publicado em 2014

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Por Barr, Paul M., Miller, Thomas P., Friedberg, Jonathan W., Peterson, Derick R., Baran, Andrea M., Herr, Megan, Spier, Catherine M., Cui, Haiyan, Roe, Denise J., Persky, Daniel O., Casulo, Carla, Littleton, Jamie, Schwartz, Mark, Puvvada, Soham, Landowski, Terry H., Rimsza, Lisa M., Dorr, Robert T., Fisher, Richard I., Bernstein, Steven H., Briehl, Margaret M.
Publicado em 2014